- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Belite Bio Announces $25 Million Registered Direct Offering
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
- Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
- Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
- Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
- Belite Bio to Participate in the BTIG Ophthalmology Day
More ▼
Key statistics
On Wednesday, Belite Bio Inc (BLTE:NAQ) closed at 41.02, -15.60% below its 52-week high of 48.60, set on Feb 12, 2024.
52-week range
Open | 40.44 |
---|---|
High | 41.15 |
Low | 40.44 |
Bid | 39.70 |
Offer | 41.39 |
Previous close | 40.60 |
Average volume | 25.50k |
---|---|
Shares outstanding | 29.75m |
Free float | 11.38m |
P/E (TTM) | -- |
Market cap | 1.21bn USD |
EPS (TTM) | -1.24 USD |
Data delayed at least 15 minutes, as of May 01 2024 21:00 BST.
More ▼